The government and academic medical centers need to rethink their technology transfer policies, which have allowed the price of specialty drugs to soar to unsustainable heights.
The latest targeted therapies for cancer and genetic diseases are coming to market with price tags approaching a half-million dollars per patient. What most have in common are their origins in academic or government labs funded by the National Institutes of Health.
